Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer.
Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, Reynolds KL. Zubiri L, et al. Among authors: durbin sm. J Immunother Cancer. 2021 Sep;9(9):e002886. doi: 10.1136/jitc-2021-002886. J Immunother Cancer. 2021. PMID: 34544895 Free PMC article.
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis.
Badran YR, Zou F, Durbin SM, Dutra BE, Abu-Sbeih H, Thomas AS, Altan M, Thompson JA, Qiao W, Leet DE, Lai PY, Horick NK, Postow MA, Faleck DM, Wang Y, Dougan M. Badran YR, et al. Among authors: durbin sm. J Immunother Cancer. 2023 Jun;11(6):e007195. doi: 10.1136/jitc-2023-007195. J Immunother Cancer. 2023. PMID: 37349130 Free PMC article.
Time Toxicity Experienced by Early-Phase Cancer Clinical Trial Participants.
Durbin SM, Lundquist DM, Pelletier A, Jimenez R, Petrillo L, Kim J, Lynch K, Healy M, Johnson A, Ollila N, Yalala V, Malowitz B, Kehlmann A, Chevalier N, Turbini V, Bame V, Heldreth H, Silva J, McIntyre C, Juric D, Nipp RD. Durbin SM, et al. JCO Oncol Pract. 2024 Sep;20(9):1252-1262. doi: 10.1200/OP.23.00811. Epub 2024 Jun 10. JCO Oncol Pract. 2024. PMID: 38857457
Financial toxicity in early-phase cancer clinical trial participants.
Durbin SM, Lundquist D, Pelletier A, Petrillo LA, Bame V, Turbini V, Heldreth H, Lynch K, Boulanger M, Lam A, McIntyre C, Ferrell BR, Jimenez R, Juric D, Nipp RD. Durbin SM, et al. Cancer. 2025 Jan 1;131(1):e35586. doi: 10.1002/cncr.35586. Epub 2024 Oct 10. Cancer. 2025. PMID: 39387163
Financial toxicity in cancer care: origins, impact, and solutions.
Abrams HR, Durbin S, Huang CX, Johnson SF, Nayak RK, Zahner GJ, Peppercorn J. Abrams HR, et al. Among authors: durbin s. Transl Behav Med. 2021 Nov 30;11(11):2043-2054. doi: 10.1093/tbm/ibab091. Transl Behav Med. 2021. PMID: 34850932 Review.
104 results